The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The company’s Growth Portfolio delivered $6.2 billion in revenue
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
Gambhir brings over 35 years of rich experience in strategic finance, governance, business transformation, and leadership
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Subscribe To Our Newsletter & Stay Updated
